Paritaprevir

Paritaprevir (previously known as ABT-450) is an acylsulfonamide inhibitor of the NS3-4A serine protease manufactured by Abbott Laboratories that shows promising results as a treatment of hepatitis C. When given in combination with ritonavir and ribavirin for 12 weeks, the rate of sustained virologic response at 24 weeks after treatment has been estimated to be 95% for those with hepatitis C virus genotype 1. Resistance to treatment with paritaprevir is uncommon, because it targets the binding site, but has been seen to arise due to mutations at positions 155 and 168 in NS3.^p. 248

Contents

• How to pronounce ombitasvir paritaprevir ritonavir dasabuvir viekira pak memorizing pharmacology
• Paritaprevir ritonavir ombitasvir dasabuvir for hcv gt1 video abstract 80226
• References

Paritaprevir is a component of Viekira Pak and Technivie.